Search results for "Antimuscarinic"

showing 3 items of 3 documents

A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis

2012

Abstract Context Nocturia is a common urologic symptom that has been covered in a variety of reported studies in the literature but is not specifically covered in current guidelines. Objective To comprehensively review the literature pertaining to the definition, etiologies, and consequences of nocturia and assess the evidence supporting the use of conservative medical and interventional therapy. Evidence acquisition A literature search was conducted using the keyword nocturia , restricted to articles in the English language, after 2000 and before April 2012, in PubMed/Medline, Embase, Scopus, Web of Science, and Cochrane Library databases. Regarding treatment modalities, studies were inclu…

MaledesmopressinPathologyAnti-Inflammatory AgentsCochrane Libraryurologic and male genital diseaseslaw.inventionsystematic reviewRandomized controlled trialRisk FactorslawEpidemiologyOdds RatioPrevalencea1-blockersDesmopressina1-blockers; alpha(1)-blockers; antimuscarinics; desmopressin; meta-analysis; nocturia; nocturnal polyuria; systematic review; α1-blockersEvidence-Based MedicineAntidiuretic AgentsDiagnostic Techniques UrologicalMiddle AgedPathophysiologyfemale genital diseases and pregnancy complicationsTreatment OutcomeMeta-analysisUrologic Surgical ProceduresFemaleNocturiaα1-blockersmedicine.symptommedicine.drugmedicine.medical_specialtyUrologyMEDLINEMuscarinic Antagonistsalpha(1)-blockersPredictive Value of TestsInternal medicinemedicineHumansNocturiaIntensive care medicineantimuscarinicsAgedChi-Square Distributionbusiness.industrynocturnal polyuriaEvidence-based medicinemeta-analysisClinical trialUrodynamicsEndocrinologyAdrenergic alpha-1 Receptor AntagonistsbusinessEuropean urology
researchProduct

Tiotropium in asthma: Back to the future of anticholinergic treatment

2017

Abstract Asthma is among the most common chronic diseases worldwide; however, despite progresses in the understanding of the patho-physiological mechanisms and advances in the development of new therapeutic options and strategies, the disease remains uncontrolled in a not trivial proportion of subjects. Thus, the need of new molecules to treat the underlying biological and functional abnormalities and to control symptoms is strongly advocated by clinicians. In this scenario, the most recent GINA guidelines have included the use of tiotropium bromide in the most severe and uncontrolled forms of the disease, in addition to treatment with inhaled corticosteroid plus long acting beta adrenergic…

lcsh:Immunologic diseases. AllergyEndotypeAllergymedicine.medical_specialtyExacerbationmedicine.drug_classPopulationAntimuscarinicImmunologyReviewDiseaseAnticholinergicSettore MED/10 - Malattie Dell'Apparato RespiratorioEndotype03 medical and health sciences0302 clinical medicineControlmedicineAnticholinergicImmunology and Allergy030212 general & internal medicineeducationIntensive care medicineMolecular BiologyAsthmaeducation.field_of_studybusiness.industryTiotropiumExacerbationTiotropium bromidemedicine.diseaseAsthmaPhenotype030228 respiratory systemBronchodilationlcsh:RC581-607businessmedicine.drug
researchProduct

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

2007

Abstract Antimuscarinic therapy is the primary treatment for overactive bladder. Long-term persistence with the therapy can be problematical, and has been linked to both efficacy and tolerability. A number of specific contributory factors to poor persistence can be identified, such as adverse effects of medication, insufficient beneficial effects, inadequate follow-up after initiation of therapy (poor motivation), and unmet or unrealistic expectations (poor communication between the patient and physician). Open-label studies on antimuscarinics overestimate the real-life persistence, which can lead to unrealistic expectations of the physician. Dose flexibility has improved patient compliance…

medicine.medical_specialtyAntimuscarinic Agentbusiness.industryTransdermal patchUrologymedicine.diseasePatient satisfactionTolerabilityQuality of lifeOveractive bladderPillPhysical therapyMedicineAdverse effectbusinessIntensive care medicineEuropean Urology Supplements
researchProduct